Applying existing lot-tracking habits to a new category
If your practice already tracks specimens by a unique identifier for pathology, consider whether that same template, identifier in, documentation out, fits a biologics category as well.
Decide how biologics lot identifiers will be linked to inventory and patient records, and keep that record in whatever system your staff already uses consistently.
- Decide how biologics lot identifiers will be linked to inventory records
- Compare vendor documentation against any internal logging standard you already use
- Keep biologics lot records in a consistent system
- Assign a specific staff role to biologics documentation
Deciding purchasing authority across service lines
If a practice runs both medical dermatology and aesthetic services from the same account, decide whether purchasing authority for biologics stays with the supervising physician regardless of which service line places the order, and document that decision.
Confirm who handles scheduling and intake versus who holds order authorization, so account access has one clear point of accountability.
- Decide and document who holds purchasing authority across service lines
- Route orders from either service line through the same verified account, if applicable
- Clarify which staff handle scheduling and intake versus ordering
- Document which physician authorized each order
Reviewing marketing language with the same rigor as documentation
FDA reads a clinic's own marketing and social content as evidence of intended use. Review patient-facing language with counsel before it goes public, alongside sourcing and release documentation, rather than relying on a vendor's suggested wording.
FDA states there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351, and purchase and clinical-use decisions belong to the physician and their own regulatory counsel.
These products are not FDA approved or licensed for any disease or condition. Information here is for licensed healthcare professionals and is not medical or legal advice.
- Review all patient-facing biologics language with counsel before publishing
- Avoid adopting a vendor's suggested marketing language without review
- Keep claims limited to what documentation on file actually supports
- Revisit existing marketing materials periodically for continued compliance
Planning inventory across two service rhythms
If procedural and aesthetic appointments run on different scheduling rhythms, consider tracking usage separately by service line even when both draw from the same stock, to make order timing easier to adjust.
This separation can also make it easier to spot whether storage capacity needs adjustment for one side of the practice without disrupting the other.
- Consider tracking inventory usage separately by service line
- Adjust order timing independently for each service rhythm, if useful
- Monitor whether storage capacity meets combined demand
- Reassess inventory splits periodically as service mix changes
Frequently asked questions
Can a dermatology practice reuse its pathology-logging system for biologics?+
Decide how the clinic will link biologics lot identifiers to inventory and patient records. Some practices extend an existing specimen-tracking template; others build a separate log. Either can work if it is consistent.
Who authorizes biologics orders in a practice with both medical and aesthetic services?+
That is a decision for the practice to make and document. Many keep purchasing authority with the supervising physician whose NPI verifies the account, regardless of which service line places the order.
Should a dermatology practice use a vendor's suggested marketing language?+
Review any patient-facing language with your own counsel first. Marketing claims carry separate regulatory scrutiny from documentation, and a vendor's suggested wording is not a compliance review.